(Q36849874)

16 August 2017

1 reference

title

New therapies for treatment of rheumatoid arthritis (English)

1 reference

16 August 2017

1 reference

5

Paul Emery

0 references

Josef S Smolen

series ordinal

1

object named as

Josef S Smolen

1 reference

16 August 2017

2

Daniel Aletaha

1 reference

16 August 2017

Marcus Koeller

3

1 reference

PubMed ID

17570481

16 August 2017

Michael H Weisman

series ordinal

4

1 reference

PubMed ID

17570481

16 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

16 August 2017

1 reference

16 August 2017

370

1 reference

16 August 2017

9602

1 reference

16 August 2017

1861-1874

1 reference

The epidemiology of rheumatoid arthritis

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Activation and inhibition of lymphocytes by costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Regulatory/suppressor T cells in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Regulatory T-cell physiology and application to treat autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

B cells as antigen presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Osteoclast-independent bone resorption by fibroblast-like cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Cytokine production by synovial T cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The role of TNF alpha and IL-1 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

A proinflammatory role for IL-18 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Pathogenesis of rheumatoid arthritis: targeting cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Therapeutic strategies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Toll-like receptors as potential therapeutic targets for multiple diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The definition and measurement of disease modification in inflammatory rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Assessing remission in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Methods of assessing radiographic change in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Patients with rheumatoid arthritis in clinical care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Rituximab: mechanisms and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The interaction properties of costimulatory molecules revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Interleukin-18: a therapeutic target in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Emerging cytokine targets in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Inhibiting toll-like receptors in inflammatory disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

NF-kappaB at the crossroads of life and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Denosumab in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Emerging and potential therapies for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Dickkopf-1 is a master regulator of joint remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Early rheumatoid arthritis: time to aim for remission?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960784-3

7 January 2021

10.1016/S0140-6736(07)60784-3

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17570481